Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice
Opinion statement A wide range of immune modulating agents and options for cancer chemotherapeutic agents have led to decreased immunity in human hosts, thereby leading to an increase in the incidence of fungal infections. There has been a parallel increase in the availability of antifungal agents. Antifungal susceptibility testing is important for clinicians to choose or de-escalate to an appropriate antifungal agent and for epidemiological studies. Caution must be used when interpreting susceptibility results as some have not been fully validated for patient care..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Current treatment options in infectious diseases - 7(2015), 3 vom: 15. Juli, Seite 155-162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nachimuthu, Nagakrishnal [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Antifungal susceptibility testing |
|---|
| Anmerkungen: |
© Springer Science+Business Media New York 2015 |
|---|
| doi: |
10.1007/s40506-015-0056-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR036554006 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036554006 | ||
| 003 | DE-627 | ||
| 005 | 20230519142621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40506-015-0056-2 |2 doi | |
| 035 | |a (DE-627)SPR036554006 | ||
| 035 | |a (SPR)s40506-015-0056-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nachimuthu, Nagakrishnal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2015 | ||
| 520 | |a Opinion statement A wide range of immune modulating agents and options for cancer chemotherapeutic agents have led to decreased immunity in human hosts, thereby leading to an increase in the incidence of fungal infections. There has been a parallel increase in the availability of antifungal agents. Antifungal susceptibility testing is important for clinicians to choose or de-escalate to an appropriate antifungal agent and for epidemiological studies. Caution must be used when interpreting susceptibility results as some have not been fully validated for patient care. | ||
| 650 | 4 | |a Antifungal susceptibility testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CLSI |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a EUCAST |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Break points |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Molds |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Yeasts |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Epidemiological cutoff value |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antifungals |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ostrosky-Zeichner, Luis |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in infectious diseases |d Philadelphia, Pa. : Current Science, 2014 |g 7(2015), 3 vom: 15. Juli, Seite 155-162 |w (DE-627)SPR036553433 |w (DE-600)2090725-4 |x 1534-6250 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2015 |g number:3 |g day:15 |g month:07 |g pages:155-162 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40506-015-0056-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2015 |e 3 |b 15 |c 07 |h 155-162 | ||